Remove Cannabinoids Remove Clinical Trials Remove Definition Remove Medicine
article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. Global Wellness Strategies Inc. ( from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

article thumbnail

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

Cannabis Law Report

The acquisition of a distinctive company like Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way,” said Anthony Durkacz, Interim CEO of FSD Pharma. Strategic Highlights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials

Otherside Farms

Our definition of pure is no THC,” Guy said, adding that clinical study would help provide “better understanding and experience in what cannabidiol does in these different children groups, what benefit we can see, and how the results can best be measured.”. In the upcoming U.S.

article thumbnail

Getting to Know Cannabigerol with Bonni Goldstein, MD

Project CBD

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids.

article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

article thumbnail

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Veriheal

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible. Understanding of CUD.

article thumbnail

Outline – Hopgood & Ganim Lawyers: Medicinal Cannabis in Australia: issues and regulations

Cannabis Law Report

Through the Narcotic Drugs Amendment Act 2016 (Cth) and its amendments to the Narcotic Drugs Act 1967 (Cth) ( NDA ), the Australian Government commenced the legalisation of medicinal cannabis products in Australia under federal law in 2016. Australia’s medicinal cannabis industry continues to flourish. Chapter 2 of the NDA.